

Anne-Marie Mes-Masson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5505492/anne-marie-mes-masson-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
papers

9,325
citations

42
h-index

91
g-index

229
ext. papers

11,079
ext. citations

6.7
avg, IF

5.33
L-index

#	Paper	IF	Citations
210	Signaling by the tyrosine kinase Yes promotes liver cancer development.. <i>Science Signaling</i> , 2022 , 15, eabj4743	8.8	1
209	Pre-activation of autophagy impacts response to olaparib in prostate cancer cells.. <i>Communications Biology</i> , 2022 , 5, 251	6.7	0
208	Spatially mapping the immune landscape of melanoma using imaging mass cytometry.. <i>Science Immunology</i> , 2022 , 7, eabi5072	28	2
207	High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients. <i>Cancers</i> , 2022 , 14, 2790	6.6	1
206	Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. <i>Cancers</i> , 2021 , 13,	6.6	1
205	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer 2021 , 9,		6
204	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 487-494	3.2	0
203	Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
202	Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality. <i>Cancers</i> , 2021 , 13,	6.6	1
201	Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	2
200	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
199	The Biobanque québécoise de la COVID-19 (BQC19)-A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. <i>PLoS ONE</i> , 2021 , 16, e0245031	3.7	4
198	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206	9.8	6
197	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2021 , 160, 568-578	4.9	7
196	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , 2021 , 253, 41-54	9.4	15
195	Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families. <i>Npj Breast Cancer</i> , 2021 , 7, 109	7.8	0
194	Microdissected Tissue vs Tissue Slices-A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip. <i>Cancers</i> , 2021 , 13,	6.6	4

193	Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. <i>Scientific Reports</i> , 2021 , 11, 18183	4.9	8
192	A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. <i>Genome Medicine</i> , 2021 , 13, 186	14.4	2
191	PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence. <i>Cancers</i> , 2020 , 12,	6.6	3
190	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. <i>Modern Pathology</i> , 2020 , 33, 2361-2377	9.8	3
189	Ran GTPase: A Key Player in Tumor Progression and Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 345	5.7	20
188	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1098-1104	9.7	12
187	Plasma Gelsolin Inhibits CD8 T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer. <i>Cancer Research</i> , 2020 , 80, 3959-3971	10.1	7
186	Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems. <i>PLoS ONE</i> , 2020 , 15, e0244549	3.7	5
185	Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. <i>Current Drug Targets</i> , 2020 , 21, 974-995	3	2
184	Comparison and Analysis of Two Internationally Recognized Biobanking Standards. <i>Biopreservation and Biobanking</i> , 2020 , 18, 82-89	2.1	7
183	The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. <i>Oncogene</i> , 2020 , 39, 1600-1616	9.2	36
182	Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 128-135	3.2	2
181	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. <i>Gynecologic Oncology</i> , 2020 , 156, 377-388	4.9	9
180	Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
179	Comparing Perspectives of Canadian Men Diagnosed With Prostate Cancer and Health Care Professionals About Active Surveillance. <i>Journal of Patient Experience</i> , 2020 , 7, 1122-1129	1.3	2
178	Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. <i>Cancers</i> , 2020 , 12,	6.6	5
177	Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. <i>Scientific Reports</i> , 2020 , 10, 6491	4.9	14
176	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 3935	17.4	59

175	Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer. <i>Scientific Reports</i> , 2019 , 9, 13924	4.9	8
174	Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors. <i>Lab on A Chip</i> , 2019 , 19, 693-705	7.2	9
173	CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. <i>American Journal of Pathology</i> , 2019 , 189, 1451-1461	5.8	7
172	Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. <i>Nature Communications</i> , 2019 , 10, 2666	17.4	26
171	Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution. <i>Integrative Biology (United Kingdom)</i> , 2019 , 11, 130-141	3.7	4
170	Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. <i>Nature Communications</i> , 2019 , 10, 2556	17.4	81
169	A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2019 , 5, 177-188	5.3	8
168	Canadian Tissue Repository Network Biobank Certification Program: Update and Review of the Program from 2011 to 2018. <i>Biopreservation and Biobanking</i> , 2019 , 17, 530-538	2.1	6
167	Validation of the prognostic value of NF- κ B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. <i>PLoS Medicine</i> , 2019 , 16, e1002847	11.6	15
166	Exome Sequencing in and -Negative Greek Families Identifies and as Candidate Risk Genes for Hereditary Breast Cancer. <i>Frontiers in Genetics</i> , 2019 , 10, 1005	4.5	7
165	V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. <i>Oncotarget</i> , 2019 , 10, 4923-4936	3.3	7
164	A Review of International Biobanks and Networks: Success Factors and Key Benchmarks-A 10-Year Retrospective Review. <i>Biopreservation and Biobanking</i> , 2019 , 17, 512-519	2.1	5
163	Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the COEUR cohort. <i>Histopathology</i> , 2019 , 74, 663-666	7.3	2
162	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. <i>Pathology and Oncology Research</i> , 2019 , 25, 979-986	2.6	2
161	The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. <i>Prostate</i> , 2018 , 78, 697-706	4.2	13
160	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , 2018 , 18, 347	4.8	42
159	Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells. <i>Cancer Research</i> , 2018 , 78, 5561-5573	10.1	29
158	Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips. <i>Analyst, The</i> , 2018 , 143, 3829-3840	5	10

157	Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. <i>Breast Cancer Research</i> , 2018 , 20, 9	8.3	17
156	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018 , 18, 78	2.2	6
155	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. <i>Cancers</i> , 2018 , 10,	6.6	15
154	Hormonal and reproductive factors and the risk of ovarian cancer. <i>Cancer Causes and Control</i> , 2017 , 28, 393-403	2.8	21
153	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017 , 49, 856-865	36.3	141
152	Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. <i>Scientific Reports</i> , 2017 , 7, 13244	4.9	16
151	Canadian MenQ perspectives about active surveillance in prostate cancer: need for guidance and resources. <i>BMC Urology</i> , 2017 , 17, 98	2.2	5
150	Morphologic three-dimensional scanning of fallopian tubes to assist ovarian cancer diagnosis. <i>Journal of Biomedical Optics</i> , 2017 , 22, 76012	3.5	5
149	Functionally Null Missense Mutation Associates Strongly with Ovarian Carcinoma. <i>Cancer Research</i> , 2017 , 77, 4517-4529	10.1	18
148	Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer. <i>Human Pathology</i> , 2017 , 62, 33-39	3.7	11
147	Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2017 , 197, 1034-1040	2.5	9
146	Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study. <i>World Journal of Urology</i> , 2017 , 35, 595-603	4	10
145	Dimension reduction technique using a multilayered descriptor for high-precision classification of ovarian cancer tissue using optical coherence tomography: a feasibility study. <i>Journal of Medical Imaging</i> , 2017 , 4, 041306	2.6	8
144	Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. <i>Oncotarget</i> , 2017 , 8, 40152-40168	3.3	18
143	IKK β over-expression promotes the growth of prostate cancer through the C/EBP β -dependent activation of IL-6 gene expression. <i>Oncotarget</i> , 2017 , 8, 14487-14501	3.3	12
142	Robust high-performance nanoliter-volume single-cell multiple displacement amplification on planar substrates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 8484-9	11.5	37
141	Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2016 , 2, 247-258	5.3	192
140	Morphologic 3D scanning of fallopian tubes to assist ovarian cancer diagnosis 2016 ,		2

139	The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. <i>Scientific Reports</i> , 2016 , 6, 20508	4.9	25
138	STAT1-associated intratumoural T1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. <i>Journal of Pathology: Clinical Research</i> , 2016 , 2, 259-270	5.3	28
137	Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. <i>BMC Cancer</i> , 2015 , 15, 135	4.8	15
136	A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. <i>Journal of Ovarian Research</i> , 2015 , 8, 1	5.5	26
135	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015 , 163, 1011-25	56.2	1713
134	Germline TP53 mutational spectrum in French Canadians with breast cancer. <i>BMC Medical Genetics</i> , 2015 , 16, 24	2.1	15
133	CD73 is associated with poor prognosis in high-grade serous ovarian cancer. <i>Cancer Research</i> , 2015 , 75, 4494-503	10.1	142
132	Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. <i>BMC Medicine</i> , 2015 , 13, 217	11.4	14
131	Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. <i>Oncology Letters</i> , 2015 , 9, 2787-2790	2.6	5
130	Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. <i>Breast Cancer Research</i> , 2015 , 17, 45	8.3	73
129	PRP4K is a HER2-regulated modifier of taxane sensitivity. <i>Cell Cycle</i> , 2015 , 14, 1059-69	4.7	18
128	Potential Cross-Talk between Alternative and Classical NF- κ B Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay. <i>PLoS ONE</i> , 2015 , 10, e0131024	3.7	11
127	Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. <i>Genes and Cancer</i> , 2015 , 6, 378-398	2.9	18
126	Tissue Microarrays in Studying Gynecological Cancers 2014 , 65-76		0
125	RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer. <i>PLoS ONE</i> , 2014 , 9, e91000	3.7	32
124	A framework for biobank sustainability. <i>Biopreservation and Biobanking</i> , 2014 , 12, 60-8	2.1	83
123	A practical tool for modeling biospecimen user fees. <i>Biopreservation and Biobanking</i> , 2014 , 12, 234-9	2.1	11
122	The RelB alternative NF-kappaB subunit promotes autophagy in 22Rv1 prostate cancer cells in vitro and affects mouse xenograft tumor growth in vivo. <i>Cancer Cell International</i> , 2014 , 14, 67	6.4	5

121	Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. <i>European Journal of Cancer</i> , 2013 , 49, 2441-8	7.5	35
120	Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. <i>Biopreservation and Biobanking</i> , 2013 , 11, 83-93	2.1	31
119	VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. <i>Molecular Oncology</i> , 2013 , 7, 513-30	7.9	30
118	Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. <i>Cancer Genetics</i> , 2013 , 206, 103-15	2.3	8
117	Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. <i>BMC Medical Genetics</i> , 2013 , 14, 5	2.1	19
116	Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. <i>Gynecologic Oncology</i> , 2013 , 128, 356-63	4.9	44
115	Gata3 antagonizes cancer progression in Pten-deficient prostates. <i>Human Molecular Genetics</i> , 2013 , 22, 2400-10	5.6	29
114	Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform. <i>Biomicrofluidics</i> , 2013 , 7, 11805	3.2	36
113	Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience. <i>Biopreservation and Biobanking</i> , 2013 , 11, 387-96	2.1	18
112	Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. <i>Genes and Development</i> , 2013 , 27, 900-15	12.6	128
111	Positional mapping and candidate gene analysis of the mouse Ccs3 locus that regulates differential susceptibility to carcinogen-induced colorectal cancer. <i>PLoS ONE</i> , 2013 , 8, e58733	3.7	5
110	FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. <i>International Journal of Oncology</i> , 2013 , 42, 912-20	4.4	24
109	Establishment of primary cultures from ovarian tumor tissue and ascites fluid. <i>Methods in Molecular Biology</i> , 2013 , 1049, 323-36	1.4	13
108	The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 333-40	4.4	13
107	Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet). <i>Biopreservation and Biobanking</i> , 2012 , 10, 426-32	2.1	40
106	Necdin modulates proliferative cell survival of human cells in response to radiation-induced genotoxic stress. <i>BMC Cancer</i> , 2012 , 12, 234	4.8	5
105	Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. <i>BMC Cancer</i> , 2012 , 12, 379	4.8	41
104	Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest. <i>PLoS ONE</i> , 2012 , 7, e31916	3.7	10

103	BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. <i>PLoS ONE</i> , 2012 , 7, e38541	3.7	67
102	ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cells. <i>Prostate</i> , 2012 , 72, 777-88	4.2	5
101	PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. <i>Cancer Research</i> , 2012 , 72, 1529-37	10.1	58
100	p53 inhibits angiogenesis by inducing the production of Arresten. <i>Cancer Research</i> , 2012 , 72, 1270-9	10.1	42
99	Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation. <i>Cancer Prevention Research</i> , 2012 , 5, 765-77	3.2	
98	Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. <i>International Journal of Oncology</i> , 2012 , 40, 1865-80	4.4	17
97	Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012 , 34, 567-574	1.3	13
96	Stimulation of Wnt/ β -catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype. <i>PLoS ONE</i> , 2012 , 7, e41074	3.7	24
95	The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. <i>PLoS ONE</i> , 2012 , 7, e45484	3.7	39
94	NF-B p65 as a prognostic tool in prostate cancer: An immunohistochemical study from biopsy samples.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15202-e15202	2.2	
93	H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ER β ligand dependency. <i>EMBO Journal</i> , 2011 , 30, 3947-61	13	67
92	Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer. <i>Frontiers in Oncology</i> , 2011 , 1, 40	5.3	1
91	Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. <i>PLoS ONE</i> , 2011 , 6, e20705	3.7	23
90	Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. <i>PLoS ONE</i> , 2011 , 6, e28250	3.7	69
89	KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. <i>American Journal of Human Genetics</i> , 2011 , 89, 219-30	11	136
88	Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. <i>Journal of Pathology</i> , 2011 , 223, 567-73	9.4	98
87	IKK- γ (IKK γ /IKKi/IBK γ) expression and localization in prostate cancer tissues. <i>Prostate</i> , 2011 , 71, 1131-8	4.2	15
86	Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. <i>Molecular Carcinogenesis</i> , 2011 , 50, 901-12	5	22

85	Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. <i>International Journal of Cancer</i> , 2011 , 128, 2326-34	7.5	26
84	Regulation of E2Fs and senescence by PML nuclear bodies. <i>Genes and Development</i> , 2011 , 25, 41-50	12.6	117
83	Role of Pirh2 in mediating the regulation of p53 and c-Myc. <i>PLoS Genetics</i> , 2011 , 7, e1002360	6	51
82	Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action. <i>FEBS Journal</i> , 2010 , 277, 5146-60	5.7	18
81	A novel method of cell embedding for tissue microarrays. <i>Histopathology</i> , 2010 , 57, 323-9	7.3	5
80	Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. <i>Cancers</i> , 2010 , 2, 913-54	6.6	20
79	Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. <i>Translational Oncology</i> , 2010 , 3, 230-8	4.9	31
78	An essential role for Ran GTPase in epithelial ovarian cancer cell survival. <i>Molecular Cancer</i> , 2010 , 9, 272	42.1	48
77	ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , 2010 , 363, 1532-43	59.2	1208
76	Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. <i>Clinical and Experimental Metastasis</i> , 2010 , 27, 55-69	4.7	31
75	Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. <i>Familial Cancer</i> , 2010 , 9, 507-17	3	19
74	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. <i>Journal of Pathology</i> , 2010 , 220, 392-400	9.4	76
73	Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. <i>PLoS ONE</i> , 2010 , 5, e12107	3.7	33
72	Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. <i>Journal of Immunological Methods</i> , 2009 , 348, 9-17	2.5	180
71	Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. <i>Molecular Carcinogenesis</i> , 2009 , 48, 648-61	5	15
70	Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. <i>Molecular Carcinogenesis</i> , 2009 , 48, 1077-92	5	26
69	Over-expression of I κ B-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. <i>Prostate</i> , 2009 , 69, 706-18	4.2	30
68	BMP-2 signaling in ovarian cancer and its association with poor prognosis. <i>Journal of Ovarian Research</i> , 2009 , 2, 4	5.5	58

67	The chemiluminescence based Zplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles. <i>Journal of Translational Medicine</i> , 2009 , 7, 55	8.5	6
66	Mutation of FOXL2 in granulosa-cell tumors of the ovary. <i>New England Journal of Medicine</i> , 2009 , 360, 2719-29	59.2	551
65	Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 513-25	3.5	17
64	Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. <i>BJU International</i> , 2008 , 101, 1302-9	5.6	19
63	Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. <i>BMC Genomics</i> , 2008 , 9, 99	4.5	78
62	Characterization of three new serous epithelial ovarian cancer cell lines. <i>BMC Cancer</i> , 2008 , 8, 152	4.8	41
61	Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. <i>BMC Cancer</i> , 2008 , 8, 346	4.8	7
60	Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. <i>BMC Cancer</i> , 2008 , 8, 96	4.8	18
59	BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 913-20	4	15
58	Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 399-408	4.4	31
57	Ebp1 expression in benign and malignant prostate. <i>Cancer Cell International</i> , 2008 , 8, 18	6.4	11
56	Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. <i>BMC Medical Genomics</i> , 2008 , 1, 34	3.7	20
55	Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. <i>Molecular Carcinogenesis</i> , 2008 , 47, 56-65	5	23
54	Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. <i>Neoplasia</i> , 2007 , 9, 820-9	6.4	115
53	Comparative proteome analysis of human epithelial ovarian cancer. <i>Proteome Science</i> , 2007 , 5, 16	2.6	46
52	An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer. <i>Cancer</i> , 2007 , 110, 297-308	6.4	17
51	Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). <i>Molecular Carcinogenesis</i> , 2007 , 46, 872-85	5	165
50	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. <i>BJU International</i> , 2007 , 100, 303-9	5.6	28

49	NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. <i>Cellular Signalling</i> , 2007 , 19, 1093-100	4.9	24
48	A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. <i>Familial Cancer</i> , 2007 , 6, 491-7	3	24
47	Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. <i>Molecular Cancer Research</i> , 2007 , 5, 87-94	6.6	16
46	Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus. <i>Cancer Research</i> , 2007 , 67, 3387-95	10.1	13
45	NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. <i>Clinical Cancer Research</i> , 2007 , 13, 7044-52	12.9	30
44	Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines 2007 ,		5
43	From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2006 , 118, 1750-8	7.5	43
42	Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2006 , 119, 599-607 ⁵	7.5	102
41	SET complex in serous epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2006 , 119, 2119-26	7.5	50
40	Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. <i>Clinical Cancer Research</i> , 2006 , 12, 5741-5	12.9	69
39	Expression and nuclear localization of ErbB3 in prostate cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 2730-7 ^{2.9}	12.9	99
38	Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. <i>BMC Medical Genetics</i> , 2006 , 7, 23	2.1	17
37	An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. <i>Prostate</i> , 2006 , 66, 1245-56	4.2	15
36	Presence of prostate cancer metastasis correlates with lower lymph node reactivity. <i>Prostate</i> , 2006 , 66, 1710-20	4.2	24
35	OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer 2005 , 27, 1315		2
34	Identification of novel variant, 1484delG in the 3QTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. <i>International Journal of Oncology</i> , 2005 , 26, 1621-7	1	2
33	Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. <i>Oncogene</i> , 2005 , 24, 4672-87	9.2	67
32	Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. <i>Molecular Carcinogenesis</i> , 2005 , 43, 141-54	5	41

31	Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. <i>Molecular and Cellular Biochemistry</i> , 2005 , 275, 25-55	4.2	30
30	EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. <i>Prostate</i> , 2005 , 65, 130-40	4.2	50
29	Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. <i>Prostate</i> , 2005 , 65, 306-15	4.2	29
28	Signature of a silent killer: expression profiling in epithelial ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2004 , 4, 157-67	3.8	25
27	Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 497-504	3.5	45
26	Expression of NF-kappaB in prostate cancer lymph node metastases. <i>Prostate</i> , 2004 , 58, 308-13	4.2	83
25	Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. <i>International Journal of Cancer</i> , 2004 , 112, 411-9	7.5	36
24	Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. <i>Molecular Carcinogenesis</i> , 2004 , 41, 17-38	5	20
23	Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. <i>Oncogene</i> , 2003 , 22, 1568-79	9.2	29
22	Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. <i>Molecular Carcinogenesis</i> , 2002 , 34, 78-90	5	22
21	Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. <i>Genome Research</i> , 2002 , 12, 112-21	9.7	16
20	Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. <i>Oncogene</i> , 2001 , 20, 6617-26	9.2	63
19	Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. <i>Human Heredity</i> , 2001 , 52, 116-20	1.1	23
18	Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. <i>Oncogene</i> , 2000 , 19, 1466-72	9.2	22
17	Trisomy of chromosome 10 in two cases of ovarian carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2000 , 118, 65-8		3
16	Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. <i>Clinical Genetics</i> , 1999 , 55, 318-24	4	45
15	Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. <i>Molecular Carcinogenesis</i> , 1999 , 24, 218-25	5	12
14	The human TDE gene homologue: Localization to 20q13.1-13.3 and variable expression in human tumor cell lines and tissue. <i>Molecular Carcinogenesis</i> , 1999 , 26, 189-200	5	16

13	Mapping of chromosome 3p deletions in human epithelial ovarian tumors. <i>Oncogene</i> , 1998 , 17, 2359-65	9.2	36
12	Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. <i>American Journal of Obstetrics and Gynecology</i> , 1998 , 179, 403-10	6.4	53
11	Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. <i>American Journal of Human Genetics</i> , 1998 , 63, 1341-51	11	136
10	Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer. <i>Tumor Biology</i> , 1997 , 18, 167-74	2.9	8
9	Polyomavirus large T-antigen binds the "pRb related" protein p130 through sequences in conserved region 2. <i>Virus Research</i> , 1997 , 47, 85-90	6.4	8
8	Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. <i>Cancer Letters</i> , 1996 , 99, 185-9	9.9	52
7	Polyomavirus large T antigen zinc finger is not required for efficient cellular immortalization of primary rat embryo fibroblasts. <i>Virus Research</i> , 1996 , 46, 171-5	6.4	1
6	Sequence analysis of a novel cDNA which is overexpressed in testicular tumors from polyomavirus large T-antigen transgenic mice. <i>DNA Sequence</i> , 1994 , 5, 31-9		15
5	Establishment and characterization of testicular cell lines from MT-PVLT-10 transgenic mice. <i>Experimental Cell Research</i> , 1994 , 213, 12-9	4.2	14
4	Sequence analysis of the large and small subunits of human ribonucleotide reductase. <i>DNA Sequence</i> , 1992 , 2, 227-34		27
3	Testicular adenoma and seminal vesicle engorgement in polyomavirus large-T antigen transgenic mice. <i>Molecular Carcinogenesis</i> , 1992 , 5, 178-89	5	9
2	Role of the abl oncogene in chronic myelogenous leukemia. <i>Advances in Cancer Research</i> , 1987 , 49, 53-74	5.9	9
1	The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene		1